CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 24 enrolled
Drug / intervention
Metformindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03086005
NCT03086005Phase 3Completed
CompareCT.gov

A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer

Chung-Hoon Kim·interventional·Posted Mar 22, 2017·Updated May 11, 2017

In Brief

A Phase 3 clinical trial evaluating Metformin for Polycystic Ovary Syndrome. Completed, enrolled 24 participants across 1 site.

Detailed Summary

This study was performed to investigate the effects of metformin on controlled ovarian stimulation (COS), in vitro fertilization (IVF) outcomes, pregnancy outcomes, and comparison of serum and follicular fluid cytokines and hormones in patients with polycystic ovary syndrome (PCOS) undergoing IVF using gonadotropin-releasing hormone(GnRH) antagonist protocol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Ovary Syndrome
CountriesSouth Korea
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 22, 2017
Enrollment StartOct 12, 2011
Primary CompletionMay 4, 2015
Study CompletionJul 23, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 9.3 years ago

Interventions

Metformindrug